1. Market Research
  2. > Leisure
  3. > Recreational Activity
  4. > Marijuana Market Trends
US Medical Marijuana Market, Forecast to 2022

US Medical Marijuana Market, Forecast to 2022

  • July 2018
  • 98 pages
  • ID: 5482481
  • Format: PDF
  • Frost & Sullivan

Summary

Table of Contents

Medical Cannabis Revenue will Overtake Recreational in the Next 4 Years
The medical marijuana market is growing in the United States despite the fact that the Food and Drug Administration (FDA) has not yet approved any medical marijuana products.These marijuana-based products have not yet passed through the rigorous tests and clinical trials required for medical drug approvals in the United States.

At the Federal level, marijuana is still considered an illegal Schedule 1 drug.Individual states, however, have laws in place for the legal use of medical marijuana, and in some states, for the use of recreational marijuana.

Cannabidiol (CBD) products are also legally available in some US states as well as in many other countries. The market generates a lot of money, though much of that money is still considered a black market.

Many business segments are involved with the development of the medical marijuana market.Some businesses directly touch the plant product, such as growers, packers, transporters, and sellers.

Other businesses operate in the medical marijuana industry but do not touch the plant product, including legal services, marketing and brand services, data and analytical services, insurance participants and hardware or software companies.The rules differ depending upon where a company stands related to the marijuana plant.

This is a very different model than is in place for traditional pharmaceutical products.

The medical marijuana segment of the marijuana industry includes marijuana plant products, CBD products, and synthetically derived products targeting the cannabidiol receptors CB1 and CB2.There are several synthetic products currently on the markets in many countries other than the US.

As a matter of fact, in Canada, not only is medical marijuana approved for use on the national level, its use is covered by Health Canada, the national government insurance plan.

In the US, medical marijuana use is increasing, as many more states have approved it for use in several diseases.In addition, hundreds of clinical trials are underway, testing products under the watchful eye of the FDA.

It has been reported in states where medical marijuana is approved for use for the treatment of pain, there have reductions in the use of opioid drugs. This decrease in opioid use may prove to be a valuable mechanism to curb the current opioid epidemic in the US.

Legal uncertainty related to the use of medical marijuana has limited big pharma investments into this space; however in non-US locations, companies are more interested in pursuing this area of research and development.Billions of dollars are being generated through this market.

It is a growing market drawing keen interest from physicians, investors and regulators. Physician education will be crucial, as these products gain approval, as cannabis was not a part of the medical curriculum of many currently practicing physicians.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on